BeOne Medicines (ONC) Total Debt (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Total Debt of $959.1 million for Q1 2026, up 3.84% year-over-year from $923.6 million in Q1 2025, and down 5.9% quarter-over-quarter from $1.0 billion in Q4 2025.
BeOne Medicines (ONC) Total Debt (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Total Debt for 12 consecutive years, with $959.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 3.84% year-over-year to $959.1 million; the TTM figure through Mar 2026 stood at $959.1 million (up 3.84% YoY), while the FY2025 annual figure was $1.0 billion, changed 0.12% from the prior year.
- Total Debt slipped to $959.1 million in Q1 2026 per ONC's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Total Debt topped out at $1.1 billion in Q3 2024 and bottomed at $191.8 million in Q3 2025.
- Historically, Total Debt has averaged $752.8 million across 5 years, with a median of $886.0 million in 2023.
- Annual changes were most pronounced in 2023 — Total Debt surged 241.88% — and 2025, when it slumped 81.75%.
- BeOne Medicines' Total Debt stood at $259.1 million in 2022, then soared by 241.88% to $886.0 million in 2023, then advanced by 14.9% to $1.0 billion in 2024, then climbed by 0.12% to $1.0 billion in 2025, then decreased by 5.9% to $959.1 million in 2026.
- Business Quant data shows ONC's Total Debt at $959.1 million in Q1 2026, $1.0 billion in Q4 2025, and $191.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Bn |
| Mar 31, 2026 | 959.06 Mn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 191.82 Mn |
| Jun 30, 2025 | 954.49 Mn |
| Mar 31, 2025 | 923.63 Mn |
| Dec 31, 2024 | 1.02 Bn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.04 Bn |
| Mar 31, 2024 | 1.03 Bn |
| Dec 31, 2023 | 885.98 Mn |
| Sep 30, 2023 | 531.05 Mn |
| Jun 30, 2023 | 628.48 Mn |
| Mar 31, 2023 | 488.11 Mn |
| Dec 31, 2022 | 259.15 Mn |
| Sep 30, 2022 | 649.33 Mn |
| Jun 30, 2022 | 565.94 Mn |
| Mar 31, 2022 | 608.99 Mn |
| Dec 31, 2021 | 629.68 Mn |
| Sep 30, 2021 | 643.28 Mn |